ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
NCT ID: NCT04561518
Last Updated: 2025-11-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1500 participants
OBSERVATIONAL
2020-11-23
2030-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients
* Characterize the safety and effectiveness of patisiran and vutrisiran as part of routine clinical practice in the real-world clinical setting
* Describe disease emergence/progression in pre-symptomatic carriers of a known disease-causing transthyretin (TTR) variant
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with ATTR amyloidosis
Patients with a diagnosis of ATTR amyloidosis, hereditary or wild type, will be eligible for the study and will follow routine clinical care.
No interventions assigned to this group
Pre-symptomatic Carriers
Pre-symptomatic carriers with a known disease-causing TTR variant will be eligible for the study and will follow routine clinical care.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Germany Only: Patients must be treated per the summary of product characteristics (SmPC) for any approved treatment for ATTR amyloidosis
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alnylam Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Alnylam Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Trial Site
La Jolla, California, United States
Clinical Trial Site
Los Angeles, California, United States
Clinical Trial Site
Jacksonville, Florida, United States
Clinical Trial Site
Iowa City, Iowa, United States
Clinical Trial Site
Kansas City, Kansas, United States
Clinical Trial Site
Baltimore, Maryland, United States
Clinical Trial Site
Boston, Massachusetts, United States
Clinical Trial Site
New York, New York, United States
Clinical Trial Site
Durham, North Carolina, United States
Clinical Trial Site
Columbus, Ohio, United States
Clinical Trial Site
Philadelphia, Pennsylvania, United States
Clinical Trial Site
Austin, Texas, United States
Clinical Trial Site
Houston, Texas, United States
Clinical Trial Site
Salvador, , Brazil
Clinical Trial Site
São Paulo, , Brazil
Clinical Trial Site
Sofia, , Bulgaria
Clinical Trial Site
Aarhus, , Denmark
Clinical Trial Site
Copenhagen, , Denmark
Clinical Trial Site
Bordeaux, , France
Clinical Trial Site
Bron, , France
Clinical Trial Site
Créteil, , France
Clinical Trial Site
Le Kremlin-Bicêtre, , France
Clinical Trial Site
Marseille, , France
Clinical Trial Site
Berlin, , Germany
Clinical Trial Site
Giessen, , Germany
Clinical Trial Site
Hanover, , Germany
Clinical Trial Site
Jerusalem, , Israel
Clinical Trial Site
Ramat Gan, , Israel
Clinical Trial Site
Milan, , Italy
Clinical Trial Site
Naples, , Italy
Clinical Trial Site
Palermo, , Italy
Clinical Trial Site
Roma, , Italy
Clinical Trial Site
Groningen, , Netherlands
Clinical Trial Site
Lisbon, , Portugal
Clinical Trial Site
Porto, , Portugal
Clinical Trial Site
Barcelona, , Spain
Clinical Trial Site
Madrid, , Spain
Clinical Trial Site
Palma, , Spain
Clinical Trial Site
New Taipei City, , Taiwan
Clinical Trial Site
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Alnylam Clinical Trial Information Line
Role: CONTACT
Phone: 1-877-256-9526
Email: [email protected]
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ALN-TTR02-013
Identifier Type: -
Identifier Source: org_study_id